SWM
TEVA icon

Spire Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Spire Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.8K Sell
792
-88
-10% -$2.93K ﹤0.01% 1353
2026
Q1 		$26.5K Sell
880
-681
-44% -$21.9K ﹤0.01% 1335
2025
Q4 		$48.7K Sell
1,561
-2,129
-58% -$52.4K ﹤0.01% 1190
2025
Q3 		$74.5K Sell
3,690
-854
-19% -$15K ﹤0.01% 1104
2025
Q2 		$76.2K Sell
4,544
-700
-13% -$11.3K ﹤0.01% 1074
2025
Q1 		$80.6K Buy
5,244
+250
+5% +$4.47K ﹤0.01% 1118
2024
Q4 		$110K Hold
4,994
– – ﹤0.01% 1001
2024
Q3 		$90K Sell
4,994
-300
-6% -$5.25K ﹤0.01% 939
2024
Q2 		$86K Sell
5,294
-370
-7% -$5.7K ﹤0.01% 940
2024
Q1 		$79.9K Hold
5,664
– – ﹤0.01% 1060
2023
Q4 		$63.3K Buy
5,664
+80
+1% +$747 ﹤0.01% 1124
2023
Q3 		$57K Hold
5,584
– – ﹤0.01% 1128
2023
Q2 		$42K Buy
5,584
+1,375
+33% +$11.1K ﹤0.01% 1268
2023
Q1 		$37.3K Buy
4,209
+1,400
+50% +$13.8K ﹤0.01% 1331
2022
Q4 		$26K Sell
2,809
-2,058
-42% -$18K ﹤0.01% 1264
2022
Q3 		$39K Sell
4,867
-2,500
-34% -$22.1K ﹤0.01% 1051
2022
Q2 		$55K Sell
7,367
-5,970
-45% -$52K ﹤0.01% 1255
2022
Q1 		$125K Sell
13,337
-2,280
-15% -$19K ﹤0.01% 1089
2021
Q4 		$125K Sell
15,617
-133
-0.8% -$1.2K ﹤0.01% 1311
2021
Q3 		$153K Buy
15,750
+60
+0.4% +$562 ﹤0.01% 1022
2021
Q2 		$155K Sell
15,690
-5,622
-26% -$59.5K ﹤0.01% 1029
2021
Q1 		$246K Buy
+21,312
New +$244K 0.01% 969

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Spire Wealth Management's TEVA Position: Q2 2026 in Review

Spire Wealth Management reduced its Teva Pharmaceuticals (TEVA) stake by 10% in Q2 2026, selling an estimated $2.93K and leaving 792 shares worth $26.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1353.

Spire Wealth Management first reported a position in TEVA in Q1 2021 and has held it in 22 quarters since. The position peaked at $246K in Q1 2021. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Spire Wealth Management held 792 shares of Teva Pharmaceuticals worth $26.8K as of Q2 2026.
  • Spire Wealth Management sold 88 Teva Pharmaceuticals shares in Q2 2026, an estimated $2.93K.
  • Teva Pharmaceuticals made up ﹤0.01% of Spire Wealth Management's portfolio in Q2 2026, its #1353 holding.
  • Spire Wealth Management first reported a position in Teva Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • Spire Wealth Management's Teva Pharmaceuticals position peaked at $246K in Q1 2021.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Spire Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.